Recent 8-K filings for BFRI
Highest-materiality recent filing
Biofrontera closes purchase of Ameluz/RhodoLED US assets, reduces earnout to 12-15%
- Acquired all U.S. assets and rights to Ameluz and RhodoLED, including NDA, patents, manufacturing, and personnel.
- New earnout structure: 12% of net sales up to $65M, 15% above; replaces prior 25-35% perpetual payment.
-
Biofrontera Q1 revenue up 17% to $10.1M; gross margin 80%; PDUFA for sBCC set Sept 2026
Revenue $10.1M (+17% YoY); gross margin 80% (vs 62% Q1 2025) from new earnout structure.
-
Q4 2025 revenue $17.1M, up 36% YoY; net income $5.6M vs. net loss $1.4M in Q4 2024.
-
Phase 2b study: 3-hour Ameluz incubation achieved 57.97% reduction in inflammatory lesions vs 36.51% for vehicle.
-
PTAB finds Sun Pharma’s patent '028 unpatentable, a win for Biofrontera in patent dispute
PTAB issued Final Written Decision on Feb 23, 2026, invalidating all challenged claims of Sun's U.S. Patent No. 11,697,028.
-
Biofrontera Phase 3 Ameluz® PDT meets primary endpoint for AK on extremities/neck/trunk
Complete clearance 45.6% (Ameluz®) vs 16.7% (vehicle), p<0.0003 in FAS.
-
Biofrontera reports record preliminary Q4 2025 revenue of $17.0-17.5M, up ~35-39% YoY
Q4 2025 preliminary revenue $17.0-17.5M, highest quarterly revenue in history, YoY growth 35-39%.
-
Biofrontera receives Nasdaq deficiency notice for bid price below $1.00 for 34 days
Nasdaq notice on Dec 31, 2025: common stock not compliant with Listing Rule 5550(a)(2) due to closing bid below $1.00.
-
Biofrontera Q3 revenue $7.0M, net loss $6.6M; closes Ameluz asset purchase
Q3 2025 revenues $7.0M (down 22% YoY); 9-month revenues stable at $24.6M vs $24.8M.
-
Biofrontera regains Nasdaq compliance on stockholders' equity and bid price rules
Received Nov 4 notice from Nasdaq confirming compliance with Rule 5550(b)(1) (stockholders' equity).
-
Biofrontera sells Xepi® license to Pelthos for up to $10M; receives $3M at close
Sold US license of Xepi® (ozenoxacin) cream to Pelthos Therapeutics for up to $10M total consideration.
-
Biofrontera closes acquisition of U.S. rights to Ameluz; raises $2.5M in Series C preferred
Acquired all U.S. rights to Ameluz and RhodoLED from former parent Biofrontera AG per Asset Purchase Agreement dated Oct 20, 2025.
-
Biofrontera closes purchase of Ameluz/RhodoLED US assets, reduces earnout to 12-15%
Acquired all U.S. assets and rights to Ameluz and RhodoLED, including NDA, patents, manufacturing, and personnel.
-
Biofrontera Q2 rev $9.0M (+15%); net loss $5.3M; restructures AG deal, new royalty 12-15%
Q2 2025 revenue $9.0M (up 15% YoY); net loss $5.3M vs $0.3M in Q2 2024.
-
Biofrontera appoints George Jones as Chief Commercial Officer effective August 25, 2025
George Jones named CCO of Biofrontera (Nasdaq: BFRI), bringing over 25 years of commercial leadership in pharmaceuticals and biotech.
-
Biofrontera to acquire US Ameluz/RhodoLED rights; royalty 12-15%, 10% equity stake
Upfront EUR 2,593,750 payment due June 30, 2025; condition to raise $8.5M preferred equity by same date.
-
Acquired all U.S. rights to Ameluz and RhodoLED from Biofrontera AG; will pay royalty of 12% or 15% based on $65M revenue threshold.
-
Biofrontera acquires US Ameluz/RhodoLED rights, cuts royalty to 12%, gets $11M financing
Acquires all US assets for Ameluz and RhodoLED including NDA and patents from Biofrontera AG.
-
Biofrontera confirms talks with Biofrontera AG on merger or license restructuring
Negotiations with Biofrontera AG include possible combination of the two companies.
-
Biofrontera receives Nasdaq deficiency notice for equity below $2.5M
Stockholders' equity at $469,000, well below Nasdaq's $2.5M minimum requirement.
-
Biofrontera Q1 2025 revenue $8.6M (+9% YoY); net loss narrows to $4.2M
Total revenues $8.6M, +8.7% YoY; net loss $4.2M ($0.47 per share) vs $10.4M ($2.88) prior year.
-
Biofrontera receives Nasdaq bid price deficiency notice, 180 days to cure
Nasdaq notified Biofrontera on May 8, 2025 that common stock bid price closed below $1.00 for 33 consecutive business days.
-
Biofrontera reports record FY 2024 revenue $37.3M, up 9.5% YoY; Q4 net loss $1.4M
Record total revenues $37.3M for 2024, +9.5% from $34.1M in 2023; Q4 revenues $12.6M, +18.5% YoY.
-
Biofrontera issues $4.2M in 10% secured convertible notes due 2027
$4.2M private placement of 10% Senior Secured Convertible Notes due Nov 22, 2027 to principal stockholders.
-
Biofrontera Q3 revenue $9.0M (+1.5% YoY); net loss narrows; FDA approves higher Ameluz dosage
Total Q3 2024 revenue $9.0M, up 1.5% YoY (would have been +19% without Hurricane Milton delays of ~$1.5M).
-
Biofrontera reports Phase 3 sBCC study success; Ameluz-PDT primary endpoint met p<0.0001
Primary endpoint: 65.5% complete clearance vs 4.8% placebo (p<0.0001); histological clearance 75.9% vs 19.0%.
-
FDA approves Biofrontera's sNDA for up to 3 tubes of Ameluz per treatment
FDA increased max dosage from 1 to 3 tubes of Ameluz per PDT treatment for actinic keratosis.
-
Biofrontera Q2 revenue $7.8M (+34% YoY); net loss narrows to $0.3M from $9.8M
Q2 2024 total revenues $7.8M, up 34% from $5.8M in Q2 2023; catch-up from lower 1Q sales due to Change Healthcare cyber event.
-
Biofrontera Q1 revenue down 9% to $7.9M; net loss $10.4M; Ameluz license renegotiated
Q1 revenue $7.9M, down 9% YoY from $8.7M due to Change Healthcare data breach reimbursement issues.
-
Biofrontera achieves milestones on Series B-3 warrants, unlocking $8M gross proceeds
Board certified >5% YoY revenue growth (Jan-Apr 2024 vs 2023, ex-related parties) and >95% CRM adoption.
-
Biofrontera reports record FY2023 revenue of $34.1M, +19% YoY; Q4 net income $3.5M
FY2023 total revenues $34.1M (+19% YoY); operating expenses $56.7M (incl $2M one-time legal).
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.68 · Most common event other_material